Founded in 2009, Nurix, Inc. develops a new class of drugs that work by modulating the protein regulation machinery of the cell for the treatment of proliferative and degenerative diseases.
The ubiquitin proteasome system (UPS) is a regulatory pathway that directs protein degradation, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas, including oncology. Nurix's product engine leverages a deep mechanistic understanding of the UPS to deliver effective small molecule drug candidates with the potential to make a dramatic difference for patients.
The company was formerly known as Kura Therapeutics, Inc. Nurix, Inc. was incorporated in 2009. The company received $28.2 Million in two rounds of funding from the Third Rock Ventures and The Column Group.
For more detailed information, please visit: www.nurix-inc.com
Dr. Michael Rape
Dr. K. Peter Hirth Chair in Cancer Biology;
Professor, Department of Molecular and Cell Biology, UC Berkeley
Investigator, Howard Hughes Medical Institute
Blavatnik National Award
Finalist 2014 and 2015
Recognized for his seminal contributions to our understanding of ubiquitin-mediated proteolysis and molecular events controlling mitosis
Dr. Rape is a pioneer in uncovering fundamental mechanisms of cellular regulation as controlled by post-translational modification with the highly conserved protein ubiquitin. His Lab revealed novel ubiquitin chain types that control critical transitions in the human cell cycle program. By combining structural biology, biochemistry and cell biology, Dr. Rape translates his insights into the basic mechanisms of ubiquitylation into novel strategies of drug discovery.